pharma · Recipients of allogeneic stem cell transplantation
AstraZeneca
Astra Zeneca AB
Astra Zeneca AB is a pharma organization headquartered in EU. Primary therapeutic focus areas include Recipients of allogeneic stem cell transplantation. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and
Company details
- Status
- Public
- HQ
- cambridge, GB
- Employees
- 79,242
- Programs
- 1
- Drugs
- 8
- Patents
- 25
Quick answer
Astra Zeneca AB is a pharma organization headquartered in EU. Primary therapeutic focus areas include Recipients of allogeneic stem cell transplantation. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1).
Company snapshot
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio
- 1 active pipeline program(s) linked via ClinicalTrials.gov.
- 25 US patent(s) indexed to this assignee profile.
- 1 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for AstraZeneca. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
ESMO 2025 Preview: Astra and Daiichi vs. Gilead
Recent coverage
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.
EMA backs datopotamab deruxtecan for advanced lung cancer
EMA action on datopotamab deruxtecan adds a key catalyst for lung cancer tracking, even as the program’s regulatory path differs by region. For BD teams, investors, and analysts, the story now centers on approval status, label scope, and the next clinical and filing milestones.
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 2
Congress & presentations
- PresentationPhase III data readouts for key studies in oncology (H1 and H2 2026)
- CongressBIO
- CongressDIA
Momentum
Proprietary activity score for AstraZeneca.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for AstraZeneca.
- Clinical update
- Patent grant
- Patent grant
- Patent grant
- Patent grant
Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is AstraZeneca?
-
Is AstraZeneca publicly traded?
-
What drugs does AstraZeneca develop or market?
-
What are the latest developments for AstraZeneca?
-
What therapeutic areas does AstraZeneca focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.